This is a preview of subscription content, log in to check access.
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
Roudaut R, Serri K, Lafitte S (2009) Thrombosis of prosthetic heart valves: diagnosis and therapeutic considerations. Heart 93:137–142
Foley PW, Sharma R, Kalra PR (2007) Beware of prosthetic valve thrombosis despite therapeutic anticoagulation. Emerg Med J 24:e18
Lengyel M (2008) Diagnosis and treatment of left-sided prosthetic valve thrombosis. Expert Rev Cardiovasc Ther 6:85–93
Eriksson BI, Dahl OE, Rosencher N et al (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370:949–956
Schulman S, Kearon C, Kakkar AK et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 364:2342–2352
Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151
Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992
Redondo S, Martinez MP, Ramajo M, Navarro-Dorado J, Barez A, Tejerina T (2011) Pharmacological basis and clinical evidence of dabigatran therapy. J Hematol Oncol 4:53
Van de Werf F, Brueckmann M, Connolly SJ, Friedman J, Granger CB et al (2012) A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J 163:931–937
US Food and Drug Administration (2012) FDA drug safety communication: Pradaxa (dabigatran etexiliate mesylate) should not be used in patients with mechanical prosthetic heart valves. US Department of Health and Human Services. www.fda.gov/Drugs/DrugSafety/ucm332912.htm. Accessed 10 April 2013
Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, EM PL, Warfarin Reversal Consensus Group (2004) Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 181:492–497
Dittus C, Ansell J (2013) The evolution of oral anticoagulant therapy. Prim Care 40:109–1034
Vahanian A, Baumgartner H, Bax J et al (2007) Guidelines on the management of valvular heart disease: the task force on the management of valvular heart disease of the European society of cardiology. Eur Heart J 28:230–268
Salem DN, O’Gara PT, Madias C, Pauker SG, American College of Chest Physicians (2008) Valvular and structural heart disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133(6 Suppl):593S–629S
Bonow RO, Carabello BA, Chatterjee K et al (2008) 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the society of cardiovascular anesthesiologists, society for cardiovascular angiography and interventions, and society of thoracic surgeons. J Am Coll Cardiol 52:e1–e142
Prince J, Hynes M, Labinaz M, Ruel M, Boodhwani M (2012) Mechanical valve thrombosis with dabigatran. J Am Coll Cardiol 60:1710–1711
Stewart RA, Astell H, Young L, White HD (2012) Thrombosis on a mechanical aortic valve whilst anticoagulated with dabigatran. Heart Lung Circ 21:53–55
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Coulter, S., Campos, K. Thrombosis on a mechanical mitral valve anticoagulated with dabigatran. J Thromb Thrombolysis 37, 84–86 (2014). https://doi.org/10.1007/s11239-013-0935-7
- Mechanical valve